Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03080597 · ClinicalTrials.gov registry record · NA
PrEP for HBCUs (Study 2)
A NA study of At Risk for HIV, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 16
- Enrollment target
- 1
- Study location
NCT03080597: Completed NA study of At Risk for HIV, sponsored by Duke University.
NCT03080597 is a NA study of At Risk for HIV that has completed, run by Duke University. The registered enrollment target is 16 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03080597, a NA study of At Risk for HIV, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 16 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' overall goals are to target (a) pre-exposure prophylaxis (PrEP) uptake by addressing access and acceptability and (b) PrEP adherence among Historically Black Colleges and Universities (HBCU) students.
Primary Outcome
As measured by the number of times per day that subjects initiate an interaction with PrEP Smart
Conditions Studied
Interventions
- DEVICE PrEP Smart app
Study Locations (1)
North Carolina
- Duke University Medical Center - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2017-03-01 |
| Est. Completion | 2018-10-01 |
| Phase | NA |
What the finished NCT03080597 record still lists
NCT03080597 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 16 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 1 condition, with At Risk for HIV appearing as the primary indexed condition, and to 1 intervention - of which PrEP Smart app is the first listed.
NCT03080597 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT03080597 about?
NCT03080597 is a clinical study titled "PrEP for HBCUs (Study 2)". The investigators' overall goals are to target (a) pre-exposure prophylaxis (PrEP) uptake by addressing access and acceptability and (b) PrEP adherence among Historically Black Colleges and Universities (HBCU) students.
What is the current status of trial NCT03080597?
This trial is currently completed. It is a NA study. The enrollment target is 16 participants. The study started on 2017-03-01. Estimated completion is 2018-10-01.
What conditions does trial NCT03080597 study?
This clinical trial studies the following conditions: At Risk for HIV.
What interventions are being tested in trial NCT03080597?
The interventions under investigation include: PrEP Smart app (DEVICE).
Who is sponsoring clinical trial NCT03080597?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03080597 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03080597's enrollment target sits among peer trials
16 1871st of 2000 higher than 120 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02422641 · 16 participants · Phase 2
Prospective Evaluation Of High-Dose Systemic Methotrexate In Patients With Breast Cancer And Leptomeningeal Metastasis
- NCT02851758 · 16 participants · NA
Transplantation of Autologously Derived Mitochondria Following Ischemia
- NCT03291028 · 16 participants
Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma
- NCT03425526 · 16 participants · Phase 1
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI